Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma

Status:
Not yet recruiting

Trial end date:
2023-02-28

Target enrollment:

Participant gender:

This is a phase I/II, open-label, multicenter study to assess the efficacy and safety of IM19 CAR-T cells in adult R/R Mantle Cell Lymphoma subjects

Phase 1/Phase 2

Beijing Immunochina Medical Science & Technology Co., Ltd.

Cyclophosphamide
Fludarabine